{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:57:00Z","timestamp":1785787020447,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04522-2","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:09:40Z","timestamp":1785740980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermediate rectal dose is associated with late toxicity after prostate SBRT: a dose\u2013volume histogram principal component analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-1015","authenticated-orcid":false,"given":"Amadeo J. Wals","family":"Zurita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Illescas","family":"Vacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor Miras","family":"del R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rubio","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Vicente","family":"Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Saavedra","family":"Bejarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ure\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica Ortiz","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Carrasco","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"8","key":"4522_CR1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4.","journal-title":"Lancet Oncol"},{"issue":"17","key":"4522_CR2","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884\u201390. https:\/\/doi.org\/10.1200\/JCO.2016.71.7397.","journal-title":"J Clin Oncol"},{"issue":"10196","key":"4522_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","journal-title":"Lancet"},{"issue":"10","key":"4522_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4.","journal-title":"Lancet Oncol"},{"issue":"15","key":"4522_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391(15):1413\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2403365.","journal-title":"N Engl J Med"},{"issue":"2","key":"4522_CR6","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2(2):e188006. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.8006.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"4522_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;104(4):778\u201389. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.051.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"4522_CR8","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1088\/0031-9155\/58\/8\/2581","volume":"58","author":"O Acosta","year":"2013","unstructured":"Acosta O, Drean G, Ospina JD, Simon A, Haigron P, Lafond C, et al. Voxel-based population analysis for correlating local dose and rectal toxicity in prostate cancer radiotherapy. Phys Med Biol. 2013;58(8):2581\u201395. https:\/\/doi.org\/10.1088\/0031-9155\/58\/8\/2581.","journal-title":"Phys Med Biol"},{"issue":"3 Suppl","key":"4522_CR9","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S2\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"4522_CR10","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","volume":"76","author":"JM Michalski","year":"2010","unstructured":"Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S123\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.03.078.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4522_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.ijrobp.2004.07.715","volume":"61","author":"STH Peeters","year":"2005","unstructured":"Peeters STH, Heemsbergen WD, van Putten WLJ, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61(4):1019\u201334. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.07.715.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4522_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ijrobp.2003.12.033","volume":"59","author":"SL Tucker","year":"2004","unstructured":"Tucker SL, Cheung R, Dong L, Liu HH, Thames HD, Huang EH, et al. Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59(2):353\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.12.033.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4522_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ijrobp.2004.11.013","volume":"62","author":"LA Dawson","year":"2005","unstructured":"Dawson LA, Biersack M, Lockwood G, Eisbruch A, Lawrence TS, Ten Haken RK. Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys. 2005;62(3):829\u201337. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.11.013.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4522_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijrobp.2007.04.066","volume":"69","author":"M S\u00f6hn","year":"2007","unstructured":"S\u00f6hn M, Alber M, Yan D. Principal component analysis-based pattern analysis of dose-volume histograms and influence on rectal toxicity. Int J Radiat Oncol Biol Phys. 2007;69(1):230\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.04.066.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4522_CR15","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/j.ijrobp.2011.01.024","volume":"81","author":"D Vesprini","year":"2011","unstructured":"Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, et al. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81(4):e415\u201321. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.01.024.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"4522_CR16","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1088\/0031-9155\/54\/17\/005","volume":"54","author":"F Buettner","year":"2009","unstructured":"Buettner F, Gulliford SL, Webb S, Partridge M. Using dose-surface maps to predict radiation-induced rectal bleeding: a neural network approach. Phys Med Biol. 2009;54(17):5139\u201353. https:\/\/doi.org\/10.1088\/0031-9155\/54\/17\/005.","journal-title":"Phys Med Biol"},{"issue":"21","key":"4522_CR17","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1088\/0031-9155\/54\/21\/006","volume":"54","author":"F Buettner","year":"2009","unstructured":"Buettner F, Gulliford SL, Webb S, Sydes MR, Dearnaley DP, Partridge M. Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397). Phys Med Biol. 2009;54(21):6535\u201348. https:\/\/doi.org\/10.1088\/0031-9155\/54\/21\/006.","journal-title":"Phys Med Biol"},{"issue":"1","key":"4522_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eururo.2025.07.007","volume":"89","author":"R Ratnakumaran","year":"2026","unstructured":"Ratnakumaran R, Brand DH, Sasitharan A, Mohajer J, Hinder V, Khan A, et al. Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B Study. Eur Urol. 2026;89(1):71\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2025.07.007. (Epub 2025).","journal-title":"Eur Urol"},{"issue":"8","key":"4522_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00066-024-02343-2","volume":"201","author":"G Ozyigit","year":"2025","unstructured":"Ozyigit G, Hurmuz P, Bayatfard P, Tilki B, Yedekci Y, Yilmaz MT. Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric parameters and prostate volume. Strahlenther Onkol. 2025;201(8):788\u201398. https:\/\/doi.org\/10.1007\/s00066-024-02343-2.","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"4522_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.euo.2025.03.011","volume":"8","author":"WL Ong","year":"2025","unstructured":"Ong WL, Quon H, Ong A, Cheung P, Chu W, Chung H, et al. Every other day or once a week: long-term oncological outcomes in the phase 2 PATRIOT trial of prostate stereotactic ablative body radiotherapy. Eur Urol Oncol. 2025;8(4):909\u201313. https:\/\/doi.org\/10.1016\/j.euo.2025.03.011.","journal-title":"Eur Urol Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04522-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:03:08Z","timestamp":1785783788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04522-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":20,"alternative-id":["4522"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04522-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A large language model (ChatGPT, OpenAI) was used as a writing and editorial support tool to assist with language refinement, structural editing, and consistency checking of the manuscript and supplementary materials. The model did not generate original data, perform statistical analyses, or influence study design, data interpretation, or scientific conclusions. All analyses, interpretations, and final content decisions were made by the authors.","order":2,"name":"Ethics","label":"Use of artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}}]}}